WGS
NASDAQGeneDx Holdings Corp.
News25/Ratings8
News · 26 weeks54-79%
2025-10-262026-04-19
Mix3090d
- Insider17(57%)
- SEC Filings5(17%)
- Other4(13%)
- Earnings3(10%)
- Analyst1(3%)
Latest news
25 items- PRGeneDx to Report First Quarter 2026 Financial Results on Monday, May 4, 2026GeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the first quarter of 2026 after the market closes on Monday, May 4, 2026. Management will host a conference call that day to discuss first quarter 2026 financial and operating results at 4:30 p.m. Eastern Time. Conference Call Details Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at https://ir.genedx.com/. About GeneDx GeneDx's (NASDAQ:WGS) mission is t
- INSIDERSEC Form 4 filed by Feeley Kevin4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- INSIDERSEC Form 4 filed by Stueland Katherine4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Stueland Katherine sold $1,319,291 worth of shares (17,179 units at $76.80) and converted options into 30,671 shares, increasing direct ownership by 30% to 58,447 units (SEC Form 4)4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Feeley Kevin converted options into 11,012 shares and sold $438,203 worth of shares (5,706 units at $76.80), increasing direct ownership by 24% to 27,148 units (SEC Form 4)4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- PRLandmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome TestingNew data shows up to 61% reduction in healthcare costs for children with neurodevelopmental disorders in the 12 months following ExomeDx™ and GenomeDx™ testing, regardless of the test result GeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced findings from the Genetic Sequencing Analysis has Value in Economic Savings (SAVES)-Kids Study, a real-world data Health Economics and Outcomes Research (HEOR) analysis led by GeneDx that focuses on the economic impact of whole exome sequencing (WES) and whole genome sequencing (WGS) in children with neurodevelopmental disorders, like epilepsy and developmental delay and in
- INSIDERSEC Form 4 filed by GeneDx Holdings Corp.4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- INSIDERSEC Form 4 filed by GeneDx Holdings Corp.4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- PRGeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type CProgram to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC GeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (NASDAQ:ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing Program is designed to expand access to GeneDx's industry-leading ExomeDx™ test for patients with suspected Niemann-Pick disease type C, helping clinicians reach accurate diag
- INSIDERCHIEF FINANCIAL OFFICER Feeley Kevin was granted 1,986 shares, increasing direct ownership by 11% to 20,660 units (SEC Form 4)4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Stueland Katherine was granted 3,404 shares, increasing direct ownership by 9% to 42,087 units (SEC Form 4)4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- INSIDERDirector Meister Keith A. bought $13,460,090 worth of shares (169,521 units at $79.40) (SEC Form 4)4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Dechairo Bryan4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Feeley Kevin was granted 15,262 shares and sold $486,370 worth of shares (6,187 units at $78.61), increasing direct ownership by 95% to 18,674 units (SEC Form 4)4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Stueland Katherine was granted 47,684 shares and sold $2,001,371 worth of shares (25,459 units at $78.61), increasing direct ownership by 135% to 38,683 units (SEC Form 4)4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Feeley Kevin converted options into 718 shares and sold $22,248 worth of shares (287 units at $77.52), increasing direct ownership by 5% to 9,599 units (SEC Form 4)4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- SECGeneDx Holdings Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation8-K - GeneDx Holdings Corp. (0001818331) (Filer)
- PRGeneDx to Participate in Upcoming Investor ConferencesGeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company management will participate in upcoming investor conferences: TD Cowen 46th Annual Health Care Conference Boston, MA Fireside Chat: Monday, March 2 at 1:50 p.m. ET Barclays 28th Annual Global Healthcare Conference Miami Beach, FL Presentation: Wednesday, March 11 at 3:00 p.m. ET Live and archived webcasts of the presentations will be available on the "Events" section of the GeneDx investor relations website at ir.genedx.com/news-events/events. About GeneDx GeneDx's (NASDAQ:WGS) mission is to empower everyone to live their heal
- SECSEC Form S-8 filed by GeneDx Holdings Corp.S-8 - GeneDx Holdings Corp. (0001818331) (Filer)
- SECSEC Form 10-K filed by GeneDx Holdings Corp.10-K - GeneDx Holdings Corp. (0001818331) (Filer)
- SECGeneDx Holdings Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - GeneDx Holdings Corp. (0001818331) (Filer)
- PRGeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026Reported fourth quarter 2025 revenues of $121.0 million with 32% year-over-year growth in exome and genome test revenue (42% excluding a one-time 2024 benefit) Accelerated exome and genome volume growth to 34% year-over-year Reported fourth quarter 2025 adjusted gross margin1 of 71% Reported fourth quarter 2025 adjusted net income1 of $4.4 million Reaffirmed full year 2026 guidance of $540 to $555 million in revenue with 33-35% exome and genome growth GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for t
- PRTIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List of the World's Most Influential Leaders in HealthRecognition highlights growing global impact of rare disease diagnosis and the role of genomics in transforming health outcomes GeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that its President and Chief Executive Officer Katherine Stueland has been named to the TIME100 Health 2026 list – TIME's annual recognition of the 100 individuals who most influenced global health over the past year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260211797482/en/TIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List of the World's Most In
- ANALYSTGeneDx upgraded by Wells Fargo with a new price targetWells Fargo upgraded GeneDx from Equal Weight to Overweight and set a new price target of $155.00
- INSIDERChief Operating Officer Dechairo Bryan sold $510,874 worth of shares (5,961 units at $85.70), closing all direct ownership in the company (SEC Form 4)4 - GeneDx Holdings Corp. (0001818331) (Issuer)